| Identification | Back Directory | [Name]
Amoscanate | [CAS]
26328-53-0 | [Synonyms]
GO 9333
CGP-4540
C-9333 GO
CCRIS 4111
CIBA-9333 GO
Nithiocyamine
amoscanate USP/EP/BP
4-Nitro-4'-iso-thiocyanate diphenyl amine
4-Isothiocyanato-N-(4-nitrophenyl)benzenamine
Benzenamine, 4-isothiocyanato-N-(4-nitrophenyl)- | [Molecular Formula]
C13H9N3O2S | [MOL File]
26328-53-0.mol | [Molecular Weight]
271.29 |
| Chemical Properties | Back Directory | [Melting point ]
196-198° | [Boiling point ]
469.7±30.0 °C(Predicted) | [density ]
1.3474 (rough estimate) | [refractive index ]
1.6740 (estimate) | [form ]
Solid | [pka]
-3.50±0.40(Predicted) | [color ]
Crystals from acetone |
| Hazard Information | Back Directory | [Chemical Properties]
Orange-yellow crystalline powder, odorless and tasteless. Melting point 196-198°C. Insoluble in water, slightly soluble in acetone, chloroform, benzene and ethanol. | [Uses]
Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma[1]. | [Definition]
ChEBI: Amoscanate is an isothiocyanate that is phenyl isothiocyanate in which the hydrogen at the para- position has been replaced by a 4-nitroanilinyl group. It has a role as a schistosomicide drug. It is a C-nitro compound, an isothiocyanate and a secondary amino compound. It is functionally related to a diphenylamine. | [Safety Profile]
Mutation data reported. Ananthelmintic agent. | [in vivo]
Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain[1].
Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum[1].
Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma[1].
Amoscanate elicits massive ultrastructural damage in ependymal cells[1]. | Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 500 mg/kg | | Administration: | P.o.; 10 days | | Result: | Destructed ependyma and periventricular brain.
|
| Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 250 and 500 mg/kg | | Administration: | P.o.; 28 days | | Result: | Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.
|
| Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 25~500 mg/kg | | Administration: | P.o.; 20 days | | Result: | Elicited progressive necrosis of ependymal.
|
| [IC 50]
Schistosome | [References]
[1] Johanson C, et al. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. Toxicol Pathol. 2011;39(1):186-212. DOI:10.1177/0192623310394214 |
|
| Company Name: |
Pharmalego
|
| Tel: |
18321033991 |
| Website: |
https://cn.pharmalego.com/ |
|